Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Equus caballus | Ferritin light chain | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 43.9 % |
Schistosoma japonicum | Ferritin, putative | Ferritin light chain | 175 aa | 144 aa | 24.3 % |
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 142 aa | 29.6 % |
Echinococcus granulosus | expressed protein | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 44.4 % |
Echinococcus multilocularis | expressed protein | Ferritin light chain | 175 aa | 146 aa | 30.1 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | bacterioferritin BfrB | 0.001 | 0.5 | 0.5 |
Schistosoma mansoni | ferritin | 0.001 | 0.5 | 0.5 |
Treponema pallidum | bacterioferrin (TpF1) | 0.001 | 0.5 | 0.5 |
Schistosoma mansoni | ferritin light chain | 0.001 | 0.5 | 0.5 |
Echinococcus granulosus | ferritin | 0.001 | 0.5 | 0.5 |
Schistosoma mansoni | apoferritin-2 | 0.001 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Probable bacterioferritin BfrA | 0.001 | 0.5 | 0.5 |
Echinococcus multilocularis | ferritin | 0.001 | 0.5 | 0.5 |
Trichomonas vaginalis | ferritin, putative | 0.001 | 0.5 | 0.5 |
Echinococcus multilocularis | expressed protein | 0.001 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Bacterioferritin BfrB | 0.001 | 0.5 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | bacterioferritin/cytochrome b1 | 0.001 | 0.5 | 0.5 |
Schistosoma mansoni | ferritin | 0.001 | 0.5 | 0.5 |
Mycobacterium ulcerans | bacterioferritin BfrA | 0.001 | 0.5 | 0.5 |
Schistosoma mansoni | ferritin light chain | 0.001 | 0.5 | 0.5 |
Mycobacterium leprae | PROBABLE BACTERIOFERRITIN BFRA | 0.001 | 0.5 | 0.5 |
Schistosoma mansoni | ferritin | 0.001 | 0.5 | 0.5 |
Schistosoma mansoni | ferritin | 0.001 | 0.5 | 0.5 |
Schistosoma mansoni | apoferritin-2 | 0.001 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 3.2944 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 10.4179 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (binding) | = 17.7828 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 25.1189 uM | PubChem BioAssay. qHTS of alpha-syn Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 58.4789 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.